Form 4: Conduit Pharmaceuticals Director Acquires Warrants in Private Transaction
SEC Form 4
Chele Chiavacci Farley, a director of Conduit Pharmaceuticals, acquired warrants through an exchange and a private transaction, increasing her potential holdings of common stock.
Summary
- On April 22, 2024, Chele Chiavacci Farley, a director of Conduit Pharmaceuticals, engaged in transactions involving warrants.
- Farley acquired 3,000 warrants in exchange for a one-year lock-up of her common stock and a payment of $0.125 per warrant.
- Additionally, she purchased 200,332 warrants in a private transaction for $0.25 per warrant.
- The warrants have an exercise price of $3.12 and expire on April 22, 2027.
- Following these transactions, Farley directly owns 203,332 warrants.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports an insider transaction. There is no indication of positive or negative outlook.
Industry Context
This filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director's investment activity.
Key Dates
| Date | Description |
|---|---|
| 04/22/2024 | Date of warrant acquisition and exchange. |
| 04/22/2025 | Warrants become exercisable. |
| 04/22/2027 | Warrants expiration date. |
| 04/24/2024 | Date of Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Warrants, Director, CDT, Conduit Pharmaceuticals, Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.